Some press to start off with...
10/21/96 Transkaryotic Therapies Inc. (TKTX), Cambridge, Mass. Business: Gene/Cell therapy Type: IPO Raised: $37.5 million Shares: 2.5 million Price: $15 Shares after offering: 16.6 million Underwriters: Morgan Stanley; UBS Securities; and Pacific Growth Equities Overallotment: 375,000
11/25/96 Transkaryotic Therapies (TKTX) eclipsed its year-high of $17.75 (which occurred on the company's first day of trading on Oct. 17), jumping $1.875 to $18.25 on Thursday after UBS analyst Marc Ostro placed a `buy' on the company. UBS was one of the company's underwriters. TKTX was up 14 percent on the week, closing at $17.50. .
11/25/96 Transkaryotic Therapies Inc. (TKTX), Cambridge, Mass. Business: Gene/Cell therapy UBS Securities analyst Marc Ostro began coverage with a "buy" and a price target of $27. The company's gene activation technology, which stimulates protein production in human cells by activating previously dormant genes, will allow the company to develop and market most proteins without infringing any patents, he said. Erythropoietin is the first target of TKTX and partner Hoechst Marion Roussel, with trials to start in the second quarter of 1997. TKTX closed Friday at $17.50.
12/23/96 Transkaryotic Therapies Inc. (TKTX), Cambridge, Mass. Business: Gene/Cell therapy TKTX received European Patent No. 289,034 B1 related to its non-viral gene therapy technology, which genetically modifies patients' cells ex vivo to produce and deliver therapeutic proteins for extended periods. |
